Thorac Cardiovasc Surg 2024; 72(03): 188-196
DOI: 10.1055/s-0043-1763286
Original Cardiovascular

Interventional versus Surgical Treatment of Degenerated Freestyle Prosthesis

Authors

  • Denis Fedorov

    1   Department of Cardiology, MediClin Herzzentrum Lahr/Baden, Lahr, Germany
  • Robert Bauernschmitt

    2   Department of Cardiovascular Surgery, MediClin Herzzentrum Lahr/Baden, Lahr, Germany
    3   Department of Cardiovascular Surgery, UniversitätsSpital Zürich, Zurich, Switzerland
  • Jean-Pilippe Grunebaum

    1   Department of Cardiology, MediClin Herzzentrum Lahr/Baden, Lahr, Germany
  • Stefan Bauer

    2   Department of Cardiovascular Surgery, MediClin Herzzentrum Lahr/Baden, Lahr, Germany
  • Ralf Sodian

    2   Department of Cardiovascular Surgery, MediClin Herzzentrum Lahr/Baden, Lahr, Germany
  • Eberhard von Hodenberg

    1   Department of Cardiology, MediClin Herzzentrum Lahr/Baden, Lahr, Germany
Preview

Abstract

Background Bioprosthetic stentless aortic valves may degenerate over time and will require replacement. This study aimed to evaluate early- and mid-term outcomes after isolated surgical redo aortic valve replacement (redo-SAVR) and transcatheter valve-in-valve implantation (TAVI-VIV) for degenerated stentless Freestyle bioprostheses.

Methods We reviewed records of 56 patients at a single center. Overall, 37 patients (66.1%) received TAVI-VIV and 19 (33.9%) received redo-SAVR.

Results Thirty-day survival was similar in both groups (100%). One-year survival was comparable between groups (97.3% in TAVI-VIV and 100% in redo-SAVR, p = 1.0). The difference in mid-term survival after adjusting for age and EuroScore II was not significant (p = 0.41). The incidence of pacemaker implantation after TAVI-VIV was higher than after redo-SAVR (19.4% vs. 0%, p = 0.08).

Conclusion The 30-day and 1-year survival rates after both procedures were outstanding, irrespective of baseline characteristics. Isolated redo-SAVR should be favored in young patients, as the pacemaker implantation rate is lower. TAVI-VIV for degenerated Freestyle prosthesis can be a method of choice in elderly patients and those with high operative risk.

Note

This study was presented in part as a poster presentation at the 50th Annual Meeting of the German Society for Thoracic and Cardiovascular Surgery (DGTHG), 2021.




Publikationsverlauf

Eingereicht: 25. Juli 2022

Angenommen: 14. Januar 2023

Artikel online veröffentlicht:
01. März 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany